Skip to main content

Inside the NASH drug boom: New drugs for a ‘silent’ liver disease that affects millions near FDA approval

Madrigal Pharmaceuticals' resmetirom is a leading treatment candidate for the advanced form of fatty liver disease.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.